MedTrace Logo

Screening for Fabry Disease in Renal Transplantation

NCT03886714 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 592

Last updated 2025-05-16

No results posted yet for this study

Summary

Single centre, prospective pilot study examining the relevance to screen for Fabry disease in a cohort of patients who have undergone renal transplantation for nephropathy of indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary focal segmental hyalinosis with no established cause.

Conditions

Interventions

DIAGNOSTIC_TEST

Screening for Fabry disease

Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.

DIAGNOSTIC_TEST

Screen for α-galactosidase mutation

If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-25
Primary Completion
2024-12-31
Completion
2025-04-10

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886714 on ClinicalTrials.gov